| 发明名称 |
NEAT1 AS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET FOR PROSTATE CANCER |
| 摘要 |
This invention relates to diagnosis and prognosis of prostate cancer, as well as therapeutic treatment of prostate cancer. More specifically, the invention provides diagnostic and prognostic methods based on detecting nuclear enriched abundant transcript 1 (NEAT1) levels in a sample. Further provided are methods for treating prostate cancer based on targeting NEAT1 via interfering RNA. |
| 申请公布号 |
US2017037408(A1) |
申请公布日期 |
2017.02.09 |
| 申请号 |
US201515304086 |
申请日期 |
2015.04.17 |
| 申请人 |
CORNELL UNIVERSITY |
发明人 |
CHAKRAVARTY Dimple;RUBIN Mark A. |
| 分类号 |
C12N15/113;A61K31/713;A61K45/06;C12Q1/68 |
主分类号 |
C12N15/113 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method of determining the presence or risk of developing or advancing prostate cancer in a subject, comprising
detecting the level of NEAT1 in a biological sample from the subject, comparing the level of said NEAT1 relative to control, and determining the presence or risk of developing or advancing prostate cancer in the subject based on an elevated level of NEAT1 in the sample as compared to the control. |
| 地址 |
Ithaca NY US |
